Mesothelioma Treatment Alerts
Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma
A recent study has concluded that Fibulin-3 meets the necessary criteria to be considered a robust blood and effusion biomarker for pleural mesothelioma.
Clinical Trial - Phase II Study of IMC-A12 in Patients Diagnosed with Mesothelioma Who Were Previously Treated With Chemotherapy
The National Cancer Institute is currently recruiting participants to participate in a clinical trial to evaluate IMC-A12 in mesothelioma patients.
Study of Everolimus for the Treatment of Malignant Pleural Mesothelioma
A clinical trial to study the effects of Everolimus in patients with malignant pleural mesothelioma is currently underway.
Despite Onconase Trial Results Quintessence Moves Ahead
In an article posted in this column a few weeks ago, it was reported that researchers at Madison-based Quintessence Bioscience were waiting for the results of a Phase IIIb clinical trial from Alfacell Corp., a significant East Coast competitor, on an anti-cancer therapeutic compound, Onconase. QBI-139, Quintessence's lead drug candidate, is very similar to Onconase but has not yet gone through clinical testing.
A Case Report: Malignant Mesothelioma with Unexpected Contralateral Mediastinal Shift
An unusual clinical feature of mesothelioma is the presentation of contralateral mediastinal shift due to pleural mesothelioma tissue, rather than a pleural effusion.
Heated Intraoperative Intraperitoneal Chemotherapy Developed by Renowned Surgeon
Dr. Paul Sugarbaker, renowned oncologic surgeon specializing in mesothelioma at the Washington Cancer Institute, developed a leading-edge surgical procedure to treat mesothelioma called heated intraoperative intraperitoneal chemotherapy.
Comprehensive Approach for Treating Peritoneal Mesothelioma is Described
Researchers have reported that combination resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy is effective for treating malignant peritoneal mesothelioma.
Radical Decortication/Pleurectomy is the Best Surgical Approach for N2 Malignant Mesothelioma: Presented at recent STS
Stage 3 pure epithelial mesothelioma patients who underwent the more extensive treatment of radical decortication/pleurectomy appear to have significantly better results than patients who had less extensive operations.
Mesothelioma Subtype Shows Lengthier Projected Longevity: IASLC
Some malignant mesothelioma patients may have a mesothelioma prognosis that's not as grim as once widely believed, said a Nordic collaborative group.
ASCO: Recent Study Confirms Pemetrexed-Platinum Activity in Malignant Mesothelioma
Confirming results of previous studies, pemetrexed combined with either cisplatin or carboplatin demonstrated activity in previously untreated malignant pleural mesothelioma, said researchers.
Chemo Combination Improves Survival in Asbestos-Related Cancer
People with mesothelioma a form of cancer associated with asbestos exposure have a higher survival rate when treated with a combination of two cancer drugs, a large multicenter study finds.
Onconase Shows Unique Promise In Treating Mesothelioma
Alfacell Corp. said that according to the research findings published in National Academy of Sciences Journal, the company's anti-cancer drug Onconase might be one of the most effective methods of treatment for mesothelioma and lung cancer caused by asbestos.
FDA approves Alimta®-Cisplatin Combination for treatment of Asbestos-Related Cancer
The first and only drug regimen proven to help patients with an asbestos cancer live longer was approved today by the U.S. Food and Drug Administration.
Experimental Cancer Drug Tarceva
OSI Pharmaceuticals Inc. is more confident than ever of the potential of its experimental cancer drug Tarceva (erlotinib HCl), even after the failure of a similar drug in a major clinical study this summer, OSI Chairman and CEO Dr. Colin Goddard told investors at the UBS Warburg Global Life Sciences conference here on Wednesday.
Sources
New England Journal of Medicine
WTN News
7thSpace Interactive
Cancer Consultants, ID
Ed Susman
MedPage Today
Health Behavior News Service
RTT News
Reuters
Eli Lilly and Company
